$MCK

Lau Michele sold $2.7M of MCK

Lau Michele (EVP and Chief Legal Officer) sold 3,550 shares of MCKESSON CORP (MCK) at $761.09 ($2.70M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lau Michele
Published May 27, 2026, 6:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 6:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
high confidence
Mentioned
$MCK
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

Because the trade is pre-scheduled, it is less likely to be a real-time signal about near-term fundamentals; expect muted market reaction absent other news.

02

Market read

Insider selling disclosure with 10b5-1 reduces catalyst value; likely limited trading impact for MCK.

03

What to watch

The sale size ($2.70M) and post-transaction holdings (3,247 shares) may be consistent with routine diversification rather than a thesis change.

Relevance 7/10Timing: Immediate (filed today) but informationally limited; more useful for monitoring insider activity trends than for catalysts.

Background

SEC Form 4 reports insider trades; this one is an open-market sale by McKesson’s EVP and Chief Legal Officer under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

McKesson disclosed an EVP/Chief Legal Officer open-market sale of 3,550 shares ($2.70M) under a pre-arranged 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely noise unless accompanied by other fundamental news.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which generally reduces interpretive value for near-term price direction.

Market effects

Minimal; this is company-specific insider liquidity/compensation activity with no stated operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still reflect internal caution; traders may watch for clustering of sales around specific events.

Key entities

  • MCKESSON CORP

    Subject of the Form 4 insider transaction disclosure.

  • Lau Michele

    EVP and Chief Legal Officer who sold 3,550 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

$MCKMedAI 8/10

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson (NYSE:MCK) to acquire Precision Medicine Group for $2.25B, expanding its oncology and specialty care business. The deal aims to enhance clinical research and commercialization services, with Precision Medicine joining McKesson's Oncology & Multispecialty segment. McKesson has been divesting non-core assets to fund such investments, and the Oncology segment saw 33% revenue growth in Q1 2026. However, the deal's timeline and integration risks remain uncertain.

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.